Paloma Partners’s Celldex Therapeutics CLDX Stock Holding History

Paloma Partners’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,593	Closed	-$17K	–	1709
2018 Q4	$17K	Buy	+5,593	New	+$27.5K	﹤0.01%	1194
2018 Q3	–	Sell	-42,720	Closed	-$323K	–	1590
2018 Q2	$323K	Buy	42,720 +41,937	+5,356%	+$561K	0.01%	1243
2018 Q1	$27K	Buy	+783	New	+$30.3K	﹤0.01%	1875
2017 Q4	–	Sell	-1,057	Closed	-$45K	–	1926
2017 Q3	$45K	Buy	+1,057	New	+$39.6K	﹤0.01%	2051
2017 Q1	–	Sell	-688	Closed	-$37K	–	1993
2016 Q4	$37K	Buy	+688	New	+$39.1K	﹤0.01%	1936
2016 Q3	–	Sell	-1,851	Closed	-$122K	–	1869
2016 Q2	$122K	Sell	1,851 -2,713	-59%	-$172K	﹤0.01%	2056
2016 Q1	$259K	Buy	+4,564	New	+$514K	﹤0.01%	1592
2015 Q3	–	Sell	-3,686	Closed	-$1.4M	–	1641
2015 Q2	$1.4M	Buy	+3,686	New	+$1.46M	0.03%	592

Other funds holding CLDX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Paloma Partners's CLDX Position: Q1 2019 in Review

Paloma Partners sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 5,593 shares — an estimated $17K sold.

Paloma Partners first reported a position in CLDX in Q2 2015 and held it in 8 quarters. The position peaked at $1.4M in Q2 2015. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

Paloma Partners reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 5,593 Celldex Therapeutics shares in Q1 2019, an estimated $17K.
Paloma Partners first reported a position in Celldex Therapeutics in Q2 2015 and held it in 8 quarters.
Paloma Partners's Celldex Therapeutics position peaked at $1.4M in Q2 2015.
53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.